Stay updated with breaking news from Jeevan Shetty. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sofie Van Gijsel: Welcome all to the audio webcast of Galapagos' Q1 2024 Results. I'm Sofie Van Gijsel, Investor Relations representing the reporting team at Galapagos.
Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic...
Galapagos is a latecomer to CAR T-therapy, but the drugmaker hopes its technology for producing cell therapies at a clinical site will help it stand out. Galapagos has encouraging preliminary data from two early-stage programs and it just begun Phase 1/2 testing of its third cancer cell therapy.
Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the safety, efficacy, and feasibility...
Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed i...